Denali Therapeutics (DNLI) Gains from Investment Securities (2017 - 2026)
Denali Therapeutics (DNLI) reported Gains from Investment Securities of -$294000.0 for Q1 2026, down 106.75% year-over-year from $4.4 million in Q1 2025, and up 96.71% quarter-over-quarter from -$8.9 million in Q4 2025.
Denali Therapeutics (DNLI) Gains from Investment Securities (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has 10 years of Gains from Investment Securities data on file, last reported at -$294000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at -$294000.0, down 106.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.4 million (down 139.54% YoY), and the FY2025 annual result was -$772000.0, down 108.25% from the prior year.
- Gains from Investment Securities advanced to -$294000.0 in Q1 2026 per DNLI's latest filing, from -$8.9 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $11.2 million in Q3 2025 and troughed at -$8.9 million in Q4 2025.
- A 5-year average of $691250.0 and a median of $3500.0 in 2023 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities jumped 272566.67% in 2024, then tumbled 209.1% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $51000.0 in 2022, then sank by 94.12% to $3000.0 in 2023, then jumped by 272566.67% to $8.2 million in 2024, then plunged by 209.1% to -$8.9 million in 2025, then surged by 96.71% to -$294000.0 in 2026.
- Business Quant data shows DNLI's Gains from Investment Securities at -$294000.0 in Q1 2026, -$8.9 million in Q4 2025, and $11.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -294,000.00 |
| Mar 31, 2026 | -294,000.00 |
| Dec 31, 2025 | -8.92 Mn |
| Dec 31, 2025 | -8.92 Mn |
| Sep 30, 2025 | 11.17 Mn |
| Sep 30, 2025 | 11.17 Mn |
| Jun 30, 2025 | -7.38 Mn |
| Jun 30, 2025 | -7.38 Mn |
| Mar 31, 2025 | 4.36 Mn |
| Mar 31, 2025 | 4.36 Mn |
| Dec 31, 2024 | 8.18 Mn |
| Dec 31, 2024 | 8.18 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Dec 31, 2023 | 3,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Mar 31, 2023 | 4,000.00 |